JP2001503013A - ２−（１ｈ−４（５）−イミダゾイル）シクロプロピル誘導体 - Google Patents

２−（１ｈ−４（５）−イミダゾイル）シクロプロピル誘導体

Info

Publication number
JP2001503013A
JP2001503013A JP08536597A JP53659796A JP2001503013A JP 2001503013 A JP2001503013 A JP 2001503013A JP 08536597 A JP08536597 A JP 08536597A JP 53659796 A JP53659796 A JP 53659796A JP 2001503013 A JP2001503013 A JP 2001503013A
Authority
JP
Japan
Prior art keywords
imidazoyl
formula
compound
pharmaceutically acceptable
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP08536597A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503013A5 (https=
Inventor
フイリツプス，ジエイムズ・ジー
テツドフオード，クラーク・イー
カーン，アミン・モハメツド
ヤーテス，ステイーブン・エル
Original Assignee
グリアテツク・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by グリアテツク・インコーポレイテツド filed Critical グリアテツク・インコーポレイテツド
Publication of JP2001503013A publication Critical patent/JP2001503013A/ja
Publication of JP2001503013A5 publication Critical patent/JP2001503013A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Paints Or Removers (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
  • Photoreceptors In Electrophotography (AREA)
JP08536597A 1995-05-30 1996-05-29 ２−（１ｈ−４（５）−イミダゾイル）シクロプロピル誘導体 Ceased JP2001503013A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/453,359 US5652258A (en) 1995-05-30 1995-05-30 2-(4-imidazoyl) cyclopropyl derivatives
US08/453,359 1995-05-30
PCT/US1996/007833 WO1996038141A1 (en) 1995-05-30 1996-05-29 2-(1h-4(5)-imidazoyl) cyclopropyl derivatives

Publications (2)

Publication Number Publication Date
JP2001503013A true JP2001503013A (ja) 2001-03-06
JP2001503013A5 JP2001503013A5 (https=) 2004-09-24

Family

ID=23800267

Family Applications (1)

Application Number Title Priority Date Filing Date
JP08536597A Ceased JP2001503013A (ja) 1995-05-30 1996-05-29 ２−（１ｈ−４（５）−イミダゾイル）シクロプロピル誘導体

Country Status (17)

Country Link
US (2) US5652258A (https=)
EP (1) EP0837679B1 (https=)
JP (1) JP2001503013A (https=)
KR (1) KR19990022137A (https=)
CN (1) CN1100534C (https=)
AT (1) ATE207354T1 (https=)
AU (1) AU713767B2 (https=)
CA (1) CA2222101A1 (https=)
DE (1) DE69616328T2 (https=)
DK (1) DK0837679T3 (https=)
ES (1) ES2163019T3 (https=)
FI (1) FI974363L (https=)
MX (1) MX9709211A (https=)
NO (1) NO975484D0 (https=)
NZ (1) NZ308410A (https=)
PT (1) PT837679E (https=)
WO (1) WO1996038141A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525331A (ja) * 2010-04-19 2013-06-20 オリゾン・ジェノミックス・ソシエダッド・アノニマ リジン特異的脱メチル化酵素１阻害薬およびその使用

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652258A (en) * 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives
US6008240A (en) * 1997-12-15 1999-12-28 Gliatech, Inc. 2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
WO2000042023A1 (en) 1999-01-18 2000-07-20 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US7265115B2 (en) 1999-01-29 2007-09-04 Abbott Laboratories Diazabicyclic CNS active agents
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6114350A (en) * 1999-04-19 2000-09-05 Nen Life Science Products, Inc. Cyanine dyes and synthesis methods thereof
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
WO2002013821A1 (en) 2000-08-17 2002-02-21 Gliatech, Inc. Novel alicyclic imidazoles as h3 agents
US20040006120A1 (en) * 2000-08-21 2004-01-08 Yates Stephen L Use of histamine h3 receptor inverse agonists for the control of appetite and treatment of obesity
AU2002256967A1 (en) * 2000-10-30 2002-09-12 Schering Corporation Treating or reducing the risk of cardiovascular disease
BR0308118A (pt) * 2002-03-01 2005-01-11 Warner Lambert Co Método para o tratamento de osteoartrite
EP1720847A1 (en) * 2004-02-02 2006-11-15 Pfizer Products Incorporated Histamine-3 receptor modulators
EP1720861A2 (en) 2004-02-25 2006-11-15 Eli Lilly And Company Histamine h3 receptor antagonists, preparation and therapeutic uses
BRPI0509298A (pt) 2004-04-01 2007-09-18 Lilly Co Eli composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
EP1756051B1 (en) * 2004-06-02 2012-09-12 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
CN101006082B (zh) 2004-08-23 2010-09-29 伊莱利利公司 组胺h3受体药剂、制备方法和治疗用途
JP5057982B2 (ja) 2004-10-18 2012-10-24 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体阻害剤、製造及び治療的使用
BRPI0608523A2 (pt) * 2005-03-17 2010-11-16 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir receptor de histamina h3 em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, para tratar ou prevenir obesidade e para tratar ou prevenir um distúrbio ou doença, e, uso de um composto ou um sal do mesmo
AU2006232871B9 (en) 2005-04-01 2011-11-24 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
EP1707203A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
EP1717233A1 (en) * 2005-04-29 2006-11-02 Bioprojet Histamine H3-receptor ligands and their therapeutic application
EP1938838A4 (en) * 2005-09-15 2009-09-23 Banyu Pharma Co Ltd HISTAMINE H3 AGONIST FOR USE AS A THERAPEUTIC AGENT AGAINST LIPID / GLUCOSE METABOLISM
EP1942104A1 (en) 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106106A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
BR112013002164B1 (pt) 2010-07-29 2021-11-09 Oryzon Genomics S.A. Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
EP2712315B1 (en) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
EP2768805B1 (en) 2011-10-20 2020-03-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
JP6046154B2 (ja) 2011-10-20 2016-12-14 オリソン ヘノミクス エセ． アー． Ｌｓｄ１阻害剤としての（ヘテロ）アリールシクロプロピルアミン化合物
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
FR2671083B1 (fr) * 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
JPH06505265A (ja) * 1991-02-27 1994-06-16 シード・キャピタル・インベストメント・（エス・シー・アイ）・ベスローテン・フェンノートシャップ ヒスタミンｈ↓３受容体に対する作動的または拮抗的活性を有するイミダゾール誘導体
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5217986A (en) * 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
US5652258A (en) * 1995-05-30 1997-07-29 Gliatech, Inc. 2-(4-imidazoyl) cyclopropyl derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013525331A (ja) * 2010-04-19 2013-06-20 オリゾン・ジェノミックス・ソシエダッド・アノニマ リジン特異的脱メチル化酵素１阻害薬およびその使用

Also Published As

Publication number Publication date
PT837679E (pt) 2002-03-28
FI974363A7 (fi) 1997-11-28
US5652258A (en) 1997-07-29
AU713767B2 (en) 1999-12-09
DE69616328T2 (de) 2002-07-04
KR19990022137A (ko) 1999-03-25
CN1100534C (zh) 2003-02-05
DE69616328D1 (de) 2001-11-29
WO1996038141A1 (en) 1996-12-05
FI974363A0 (fi) 1997-11-28
ES2163019T3 (es) 2002-01-16
FI974363L (fi) 1997-11-28
EP0837679A4 (en) 1999-03-03
ATE207354T1 (de) 2001-11-15
EP0837679B1 (en) 2001-10-24
NZ308410A (en) 2001-06-29
AU5804796A (en) 1996-12-18
CA2222101A1 (en) 1996-12-05
EP0837679A1 (en) 1998-04-29
NO975484D0 (no) 1997-11-28
DK0837679T3 (da) 2002-02-11
MX9709211A (es) 1998-07-31
CN1192143A (zh) 1998-09-02
US5990317A (en) 1999-11-23

Similar Documents

Publication Publication Date Title
JP2001503013A (ja) ２−（１ｈ−４（５）−イミダゾイル）シクロプロピル誘導体
JPH11506106A (ja) １ｈ−４（５）−置換イミダゾール誘導体
JP2521396B2 (ja) 新規なアリ―ルエチルアミン化合物、その製法、及びそれを含有する医薬組成物
CN103200941B (zh) 用于降低眼内压的[3-(1-(1h-咪唑-4-基)乙基)-2-甲基苯基]甲醇的酯前药
WO1999020607A1 (en) Amide derivatives or salts thereof
JPH08505153A (ja) 医薬として有用であるインドールピペラジンから誘導される５−ｈｔ▲下１ｄ▼−５−ｈｔ▲下１ｂ▼受容体の選択的リガンド
JPH11500436A (ja) １−アリール−２−アシルアミノ−エタン化合物およびニューロキニン特にニューロキニン１アンタゴニストとしてのそれらの用途
US6448282B1 (en) 1H-4(5)-substituted imidazole derivatives
AU713166B2 (en) 1H-4(5)-substituted imidazole derivatives
EP0718286B1 (en) 3-Alkoxybenzylpiperidine derivatives as melatonergic agents
US6008240A (en) 2-(1H-4(5)-imidazoyl) cyclopropyl derivatives
JPH05262723A (ja) 新規ピロリジン化合物
JPH09500395A (ja) ３−アシルアミノベンゾジアゼピン類
JP2002534421A (ja) １−フェニル−４−（１−［２−アリール］シクロプロピル）メチルピペラジン：ドーパミン受容体リガンド
US6072057A (en) 1H-4(5)-cyclo-substituted imidazole derivatives as histamine H3 receptor agents
JPH09216879A (ja) （１ｈ−インドール−４−イル）−ピペリジンまたはテトラヒドロピリジンのエチルアミンおよびエチルカルボキサミド
JP2002532481A (ja) ５−ｈｔ１ａ受容体活性を有するピペラジンエチルアミド誘導体
JP3007675B2 (ja) 新規なインドール誘導体
JPH09500396A (ja) 新規フラノジアゼピン類
MXPA97009210A (en) Derivatives of imidazol ih-4 (5) -substitui

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20070412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070424

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070717

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070827

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20071205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080122